SG/PUT/VERTEX PHARMACEUTICALS/500/0.1/17.01.25 | Market Closed - Börse Stuttgart 02:34:27 2024-07-11 am EDT | ||
| 3.52 EUR | -7.12% |
|
| Current month | -21.08% | ||
| 1 month | -15.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 3.52 | -7.12% |
| 24-07-10 | 3.79 | -3.32% |
| 24-07-09 | 3.92 | -8.84% |
| 24-07-08 | 4.3 | -4.02% |
| 24-07-05 | 4.48 | -2.18% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:34 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SY01DA |
| ISIN | DE000SY01DA9 |
| Date issued | 2024-05-29 |
| Strike | 500 $ |
| Maturity | 2025-01-17 (190 Days) |
| Parity | 10 : 1 |
| Emission price | 5.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.44 € |
|---|---|
| Lowest since issue | 3.52 € |
| Spread | 0.04 € |
| Spread % | 1.09% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
492.1
USD
Average target price
473.1
USD
Spread / Average Target
-3.87%
- Stock Market
- Warrants
- Warrant
